HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ali Khoynezhad Anthony J. Tortolani Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khoynezhad, A. Articles by Tortolani, A. J. Search for Related Content PubMed PubMed Citation Articles by Khoynezhad, A. Articles by Tortolani, A. J. Related Collections Myocardial protection

Ann Thorac Surg 2004;78:1109-1118
© 2004 The Society of Thoracic Surgeons

---

Review

Apoptosis: Pathophysiology and therapeutic implications for the cardiac surgeon

^a Department of Cardiothoracic Surgery, New York Presbyterian-Cornell Medical Center, New York, New York, USA
^b Department of Medicine, New York University Medical Center, New York, New York, USA

^* Address reprint requests to Dr Khoynezhad, Department of Cardiothoracic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th St, Bronx, NY 10467, USA
akhoy{at}lycos.com

Cardiomyocyte apoptosis has been associated with the pathogenesis of heart failure as well as ischemic and inflammatory myocardial conditions. The aim of this study is to give a critical synopsis of cardiomyocyte apoptosis and identify methods to prevent or attenuate apoptosis in patients undergoing cardiac surgery. Clinical conditions and agents associated with decreased apoptotic index are early repair or replacement of valvular pathology before deterioration of ventricular function, afterload reduction with medication or intraaortic balloon pulsation in patients with acute increase in afterload or in hemodynamically compromised patients, decreasing catecholamine-induced cardiotoxicity by using ß-blockers, phosphodiesterase inhibitors, or early insertion of intraaortic balloon pulsation or ventricular assist device. Prompt coronary revascularization, which reduces myocardial ischemia time, is the most effective antiapoptotic therapy. Reduction of myocardial apoptosis associated with cardiopulmonary bypass and aortic cross-clamping are other therapeutic targets. Some investigational therapies include ischemic preconditioning and use of antiapoptotic medication such as the caspase inhibitors, antioxidants, calcium-channel blockers, the insulin-like growth factor-1, and the poly-adenosine diphosphate-ribose-synthetase inhibitors. Most of the therapeutic implications in reducing cardiomyocyte apoptosis are still in the experimental phase. Some options are already incorporated in the clinical practice of the cardiovascular surgeon. New therapeutic considerations include avoiding sustained and long-term use of catecholamines and reducing or avoiding cardiopulmonary bypass—when clinically feasible. Noncatecholamine inotropes should be preferred for patients undergoing heart failure surgery and for patients with low output syndrome after open-heart surgery. The lessons learned from apoptosis research reinforce more liberal and early insertion of intraaortic balloon pulsation or ventricular assist device in clinical low output states.

This article has been cited by other articles:

				A. Khoynezhad Promising aspects and caveats of studies on anti-apoptotic therapies in patients with heart failure Eur J Heart Fail, February 1, 2007; 9(2): 120 - 123. [Full Text] [PDF]

				P. K. Mishra Stem cell therapy for myocardial regeneration: creating hype ignoring reality Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 909 - 909. [Full Text] [PDF]

				T. Vahasilta, A. Saraste, V. Kyto, M. Malmberg, J. Kiss, E. Kentala, M. Kallajoki, and T. Savunen Cardiomyocyte Apoptosis After Antegrade and Retrograde Cardioplegia Ann. Thorac. Surg., December 1, 2005; 80(6): 2229 - 2234. [Abstract] [Full Text] [PDF]